Hemostasis and tumor immunity
Abstract Significant data have accumulated demonstrating a reciprocal relationship between cancer and the hemostatic system whereby cancer promotes life‐threatening hemostatic system dysregulation (e.g., thromboembolism, consumptive coagulopathy), and hemostatic system components directly contribute...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-05-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | https://doi.org/10.1002/rth2.12728 |
_version_ | 1797760897242890240 |
---|---|
author | Rachel Cantrell Joseph S. Palumbo |
author_facet | Rachel Cantrell Joseph S. Palumbo |
author_sort | Rachel Cantrell |
collection | DOAJ |
description | Abstract Significant data have accumulated demonstrating a reciprocal relationship between cancer and the hemostatic system whereby cancer promotes life‐threatening hemostatic system dysregulation (e.g., thromboembolism, consumptive coagulopathy), and hemostatic system components directly contribute to cancer pathogenesis. The mechanistic underpinnings of this relationship continue to be defined, but it is becoming increasingly clear that many of these mechanisms involve crosstalk between the hemostatic and immune systems. This is perhaps not surprising given that there is ample evidence for bidirectional crosstalk between the hemostatic and immune systems at multiple levels that likely evolved to coordinate the response to injury, host defense, and tissue repair. Much of the data linking hemostasis and immunity in cancer biology focus on innate immune system components. However, the advent of adaptive immunity‐based cancer therapies such as immune checkpoint inhibitors has revealed that the relationship of hemostasis and immunity in cancer extends to the adaptive immune system. Adaptive immunity‐based cancer therapies appear to be associated with an increased risk of thromboembolic complications, and hemostatic system components appear to regulate adaptive immune functions through diverse mechanisms to affect tumor progression. In this review, the evidence for crosstalk between hemostatic and adaptive immune system components is discussed, and the implications of this relationship in the context of cancer therapy are reviewed. A better understanding of these relationships will likely lead to strategies to make existing adaptive immune based therapies safer by decreasing thromboembolic risk and may also lead to novel targets to improve adaptive immune‐based cancer treatments. |
first_indexed | 2024-03-12T19:05:09Z |
format | Article |
id | doaj.art-4c79a850d86a47b8a4b58c7df0ed6f90 |
institution | Directory Open Access Journal |
issn | 2475-0379 |
language | English |
last_indexed | 2024-03-12T19:05:09Z |
publishDate | 2022-05-01 |
publisher | Elsevier |
record_format | Article |
series | Research and Practice in Thrombosis and Haemostasis |
spelling | doaj.art-4c79a850d86a47b8a4b58c7df0ed6f902023-08-02T06:18:17ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792022-05-0164n/an/a10.1002/rth2.12728Hemostasis and tumor immunityRachel Cantrell0Joseph S. Palumbo1Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine Cincinnati Ohio USACancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine Cincinnati Ohio USAAbstract Significant data have accumulated demonstrating a reciprocal relationship between cancer and the hemostatic system whereby cancer promotes life‐threatening hemostatic system dysregulation (e.g., thromboembolism, consumptive coagulopathy), and hemostatic system components directly contribute to cancer pathogenesis. The mechanistic underpinnings of this relationship continue to be defined, but it is becoming increasingly clear that many of these mechanisms involve crosstalk between the hemostatic and immune systems. This is perhaps not surprising given that there is ample evidence for bidirectional crosstalk between the hemostatic and immune systems at multiple levels that likely evolved to coordinate the response to injury, host defense, and tissue repair. Much of the data linking hemostasis and immunity in cancer biology focus on innate immune system components. However, the advent of adaptive immunity‐based cancer therapies such as immune checkpoint inhibitors has revealed that the relationship of hemostasis and immunity in cancer extends to the adaptive immune system. Adaptive immunity‐based cancer therapies appear to be associated with an increased risk of thromboembolic complications, and hemostatic system components appear to regulate adaptive immune functions through diverse mechanisms to affect tumor progression. In this review, the evidence for crosstalk between hemostatic and adaptive immune system components is discussed, and the implications of this relationship in the context of cancer therapy are reviewed. A better understanding of these relationships will likely lead to strategies to make existing adaptive immune based therapies safer by decreasing thromboembolic risk and may also lead to novel targets to improve adaptive immune‐based cancer treatments.https://doi.org/10.1002/rth2.12728cancerhemostasisimmune systemthromboembolismtumor |
spellingShingle | Rachel Cantrell Joseph S. Palumbo Hemostasis and tumor immunity Research and Practice in Thrombosis and Haemostasis cancer hemostasis immune system thromboembolism tumor |
title | Hemostasis and tumor immunity |
title_full | Hemostasis and tumor immunity |
title_fullStr | Hemostasis and tumor immunity |
title_full_unstemmed | Hemostasis and tumor immunity |
title_short | Hemostasis and tumor immunity |
title_sort | hemostasis and tumor immunity |
topic | cancer hemostasis immune system thromboembolism tumor |
url | https://doi.org/10.1002/rth2.12728 |
work_keys_str_mv | AT rachelcantrell hemostasisandtumorimmunity AT josephspalumbo hemostasisandtumorimmunity |